Astrazeneca stock: buy or sell

AZN stock price: $51.34 0.10% At close on Jan 15th, 2021

Updated on:
Jan 16th, 2021


Astrazeneca stock brief

  • Counting on Friday, it's been 3 consecutive sessions in green for Astrazeneca. Price closed on Friday at $51.34 after just changing a 0.10%.
  • Berenberg Bank and Deutsche Bank Aktiengesellschaft posted strong bullish ratings for Astrazeneca on Friday, with an average target of $0.00

Should I buy Astrazeneca stock?

All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best

Is $AZN stock a buy?

In the current situation of Astrazeneca there is not any eligible buy setup. This doesn't mean $AZN will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems

Should I sell Astrazeneca stock?

"To sell or not to sell", if you are holding Astrazeneca stock?. Like when we have to buy shares, deciding when is appropiate to sell is not a whimsical decision, and we must follow our own trading style. When selling, as well as buying, our strategies are very easy to follow but are only valid for selling shares in your porfolio, not for shorting $AZN stock

As a golden rule, you should not hold an open trade that produces greater losses than those expected at the time of the buy. The moment to sell your stock must always be ruled by the stop-loss (automatic or manual)

Is it time to sell Astrazeneca stock?

Currently, Astrazeneca stock doesn't match any of our preferred sell setups, so if you hold Astrazeneca stock and your operation is in profit probably is not time to sell now

Astrazeneca ratings

In the last month, 3 analyst ratings were published for Astrazeneca. General sentiment is bullish, with 2 out of 3 posting positive forecasts

Astrazeneca analysts' ratings - Last 30 days
Brokerage firmRating
Dec 30th, 2020
AlphaValue Neutral
Jan 15th, 2021
Berenberg Bank Strong buy
Deutsche Bank Aktiengesellschaft Strong buy

Astrazeneca stock analysis

SMAs overview

AZN stock SMAs chart

Supports and resistances

The current resistances are:

  • R1: $51.59 (0.49% above)
  • R2: $52.57 (2.40% above)
  • R3: $54.38 (5.92% above)
  • The current support levels are:

  • S1: $50.41 (-1.81% below)
  • S2: $50.12 (-2.38% below)
  • S3: $49.81 (-2.98% below)
  • Bollinger bands

    The price is moving very close to the upper Bollinger band, signaling some level of overbought in recent sessions. This is not a bearish indicator, as price can move in these levels for many days and weeks

    AZN stock Bollinger Bands chart

    Relative strength index

    When the moves for so long below 70 and above 30, without indication of overvaluation and undervaluation, the indicator gets of little use, and we find ourselves in one of these cases.

    AZN stock RSI chart

    Astrazeneca stock price history

    Astrazeneca went public priced at an adjusted price1 of $1.88 on May 1993. Since then, AZN stock surged by 2,630.85%, with an average of 97.44% per year. An investment of $1,000USD on the IPO would have a value of $27,308.51 today.

    1: Adjusted price after possible price splits or reverse-splits

    AZN stock price history chart

    Price target for Astrazeneca stock

    Nobody knows how much a stock will be priced tomorrow. However, many stock price predictions are published every day by banks, financial institutions and independent analysts.

    Along with buy or sell recommendations, brokerage institutions publish their price estimates based on the stock price action and the company fundamental data. Most of these predictions follow the release of new fundamental information by the company, and many times. If you are a small investor you don't have to invest based on these predictions.

    We don't have any target price posted in the previous 4 weeks for Astrazeneca.

    Astrazeneca stock price predictions
    Brokerage firmPrice target
    Dec 30th, 2020
    AlphaValue Not available
    Jan 15th, 2021
    Berenberg Bank Not available
    Deutsche Bank Aktiengesellschaft Not available

    Earnings and financials

    Last November, Astrazeneca ($AZN) hosted the quarterly shareholders event and released the report. Astrazeneca beat market estimates and reported of $0.47, that is a 6.82% surprise versus the previous estimates of $0.44. Despite this, reported revenues of $6.6 billion were in line with analysts forecasts.

    This compares to Earnings of $0.50 per share a year ago, so current EPS means a reduction of -6.00%. Looking at revenue, figures scarcely changed compared to $64.1B same quarter a year ago.

    Astrazeneca ($AZN) will host the earnings call mid next February.

    Astrazeneca performance

    AZN performance compared
    Astrazeneca ($AZN) -0.90% -3.10% -17.40%

    Please read:
    The opinions expressed in this article are personal and not recommendations for you to buy or sell shares. The author of this report does not know the particular conditions of the reader, his or her financial statements or his or her own best interests at any given time. All users should speak with their financial advisor before buying or selling any securities Opinions are published for general educational reasons only

    Astrazeneca summary

    Friday, January 15th, 2021
    Day range$51.13 - $51.56
    Previous close$51.29
    Session gain0.10%
    Average true range$1.07
    50d mov avg$52.61
    100d mov avg$53.33
    200d mov avg$53.14
    Earnings dateFebruary 12th, 2021

    Frequently asked questions

    What is Astrazeneca stock symbol?

    AstraZeneca PLC is a public company trading in the US stock market with the AZN symbol

    Is Astrazeneca stock a buy or sell?

    Astrazeneca received 3 ratings in the last 30 days: 2 bullish, 0 bearish and 1 neutral.

    Will AZN go up?

    There were no predictions posted by market analysts in the last 30 days for Astrazeneca.